On December 29, Alignment Healthcare Chief Medical Officer Christopher Joyce sold 16,187 shares of company stock at an average price of $18.74 per share, generating proceeds of approximately $303,344. Following this transaction, Joyce’s direct holding was reduced by 5.0%, to 307,699 shares, representing a holding valued at roughly $5.77 million. The sale was disclosed in an SEC filing and marks a notable insider disposition by one of the company’s senior executives.

This sale by Joyce was part of a coordinated round of insider sales on December 29–30 that included CEO John E. Kao (605,648 shares), President Dawn Christine Maroney (282,070 shares), CFO Robert L. Scavo (69,541 shares), and Director Hyong Kim (12,694 shares). Collectively, insiders disposed of just under one million shares over two trading sessions. While insiders do sell shares for a variety of personal reasons, the size and timing of these transactions may attract heightened investor scrutiny.

Alignment Healthcare reported third-quarter revenue of $993.7 million, up 43.5% year-over-year and ahead of the consensus estimate by $12.8 million. The company delivered $0.02 in EPS, beating expectations by $0.03, but continued to show a negative net margin of 0.57% and a negative return on equity of 16.23%. As of the latest quarter, the firm maintains a current and quick ratio of 1.61 and a debt-to-equity ratio of 1.99. Analysts project full-year EPS of -0.69, reflecting ongoing investment in clinical infrastructure and technology platform expansion.